FDA Inspection 1105180 — Swedish Orphan Biovitrum AB (Publ)
The FDA completed an inspection of Swedish Orphan Biovitrum AB (Publ) on August 29, 2019 in Stockholm. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 29, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Stockholm (Sweden)
Additional Details
Postmarket Adverse Drug Experience (PADE)